INVERSAGO-PHARMA
8.9.2020 14:02:07 CEST | Business Wire | Press release
Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité FTQ, and strong participation from existing investors Genesys, JDRF T1D Fund, Amorchem, Anges Québec Capital, adMare BioInnovations and angels.
Proceeds will be used to develop Inversago’s best-in-class peripherally-acting CB1 inverse agonist candidate INV-101 to clinical proof-of-concept, and advance the research on other selected compounds.
Clinical and scientific data suggest that the peripheral CB1 pathway is activated in a majority of metabolic and fibrotic diseases, including Prader-Willi syndrome (PWS), NASH, type-1 diabetes and diabetic nephropathy; conditions with currently inadequate treatment options. CB1 inhibition has previously shown to be an effective clinical treatment in several diseases and conditions, albeit with a CNS liability related to the central CB1 blockade. Inversago compounds are peripherally-acting only, thus adopting a safe and potent approach.
“Today’s financing is a recognition of the progress achieved over the past two years by our team,” said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “We are privileged to have secured the financing from a transatlantic syndicate of leading and committed investors like Forbion and the Fonds de solidarité FTQ. It allows the Company to make important strides towards its objective of leveraging the full medical potential of a peripheral CB1 blockade,” added Dr. Ravenelle.
In conjunction with this financing, Inversago appointed Carlo Incerti, MD, an Operating Partner at Forbion, as Chairman of the board of directors, Marco Boorsma, PhD, a General Partner at Forbion, and Patricia Allen, a biotech leader, as directors of the Company. Ms. Allen will also serve as Chair of the Audit Committee.
“I am delighted to join Inversago when the Company is transitioning from the pre-clinical stage to the first human trials,” said Carlo Incerti, MD, Chairman of the board of directors. “The science behind the CB1 pathway is extremely sound and documented and Inversago’s compounds could be very impactful in therapeutic areas that are largely unmet, like metabolic dysfunctions and fibrosis. Importantly, the peripherally-acting nature of these molecules could give them a safe and effective therapeutic window, without the known liabilities of centrally-acting blockers,” concluded Dr. Incerti.
Dr. Incerti brings to Inversago over three decades of development and commercialization experience in the biopharmaceutical industry. After a successful scientific career and prior to joining Forbion, Dr. Incerti was Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme.
Dr. Boorsma adds over 20 years of scientific, operational, business development and venture investment expertise to the Company. He manages Forbion’s Canadian investments and serves on the boards of several other bio-pharmaceutical companies.
Ms. Allen is a recognized biotech finance and operations leader who raised over US$2B in financings and business development deals during her career. She served most recently as Chief Financial Officer at Zafgen, Inc., now Larimar Therapeutics. She currently holds positions on the boards of Yumanity Therapeutics and Deciphera Pharmaceuticals, where she is also the audit committee chairperson.
“I am thrilled to join the board of Inversago, one of the few companies that remains focused on developing a treatment for people with PWS, for which I remain truly passionate,” said Ms. Allen. “I look forward to working with the other directors and the entire team at Inversago to advance their new generation of CB1 blockers in PWS and other important diseases, where the unmet medical needs remain very high. I also look forward to lending my biotechnology and public company experience and expertise at such an exciting time as the Company advances towards the clinic,” added Ms. Allen.
About Inversago Pharma
Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com
About Forbion
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 66 companies. Forbion manages well over EUR 1.25 billion across ten funds. Forbion is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fondsinvestments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. For more information, please visit: www.forbion.com .
About the Fonds de solidarité FTQ
The Fonds de solidarité FTQ (fondsftq.com ) is a capital development fund that channels the savings of Quebecers into investments. With net assets of $13.8 billion as at May 31, 2020, the Fonds has helped create and protect 221,267 jobs. The Fonds has 3,329 partner companies and 707,935 shareholders-savers.
Picture of our CEO and company logotype available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005305/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Performs First Case in the Chondrograft™ First-in-Human Clinical Study8.9.2026 15:47:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study. The study is designed to evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee. Dr. Juan Osorio and Dr. Emilio Tufiño, who both specialize in regenerative sports medicine, performed the first procedure at The Panama Clinic, Panamá. “I am pleased to be the Principal Investigator for this important study, and we are excited to be the first to initiate clinical study enrollment. The team here in Panamá looks forward to contributing the data that will support a larger clinical study and subsequent market entry,” stated Dr. Osorio. “The speed at which Dr. Osorio and the clinical team were able to identify, enroll, and treat the first patient underscores the significant unmet clini
AI Can Design the Slides, But It Can’t Fix Stage Fright: 3 in 4 Workers Get Anxious Presenting, Canva Study Finds8.9.2026 15:00:00 CEST | Press release
When AI can build the slides, what sets the presenter apart? Canva's new global study, The Presentation Paradox, finds it comes down to one thing: how you command the room.91% use AI to build and draft presentation slides each month74% feel anxious presenting at work, with Gen Z most affected (90%)68% link strong presentation skills to a recent pay rise or promotion53% currently use AI as a presentation coach55% would let an AI avatar present for them86% say great presentations come down to human connection New research from Canva, the world’s leading visual communication platform, reveals an emerging paradox at the heart of one of work’s age-old skills: even as AI makes presentations easier to create than ever, nearly three in four professionals (74%) still feel anxious about presenting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908549712/en/ Canva's Global 'The Presentation Paradox' Study Few things are as entrench
PAX Debuts The Oxblood Edit, a Limited Edition Collection Inspired by Fall’s Richest Color8.9.2026 15:00:00 CEST | Press release
PAX FOUR, MINI and ERA GO arrive in a deep oxblood finish, bringing timeless style, seasonal color, and elevated design to three of the brand’s signature devices Today PAX, a pioneering global cannabis brand, introduces The Oxblood Edit, an ultra-limited release bringing one of fall’s defining colors to three of the brand’s signature devices: PAX FOUR, PAX MINI and ERA GO. Deep, distinctive and designed to be coveted, Oxblood transforms the PAX lineup through a rich burgundy finish inspired by the worlds of fashion, interiors and industrial design. The limited collection is available beginning today at pax.com and select retailers, while supplies last. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908330141/en/ The Oxblood Edit: bringing timeless style, seasonal color, and elevated design to three of the brand's signature devices. Long associated with craftsmanship and enduring style, oxblood has reemerged across fashion
STARTEEPO Issues Letter and Presentation to the Board of Xerox Calling for Action to Unlock Shareholder Value8.9.2026 15:00:00 CEST | Press release
Urges Strategic Review of Xerox Financial Services, Including Exploring Potential Sale of All or Part of the Business UnitBelieves XFS Business Could Be Worth $7.69 Per Share -- More than Double Xerox’s Current Share PriceAsserts Investors Will Be Better Able to Value XFS Through Increased Transparency STARTEEPO SICAV a.s. (“STARTEEPO”) today issued an investor presentation and the following letter to the Board of Directors (the “Board”) of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX). STARTEEPO, which has increased its investment in Xerox to a beneficial ownership of 7.34%, in stocks and options, is urging the Board to take bold actions to unlock significant shareholder value, including by increasing transparency about Xerox Financial Services’ performance, evaluating strategic alternatives for the business unit, deleveraging the Company, and exercising continued capital discipline. Shareholders can view the investor presentation here. For more information visit
Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach8.9.2026 14:36:00 CEST | Press release
The French sculpture atelier extends the group’s expertise from everyday design to collectible art BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/ Leblon Delienne Joins LEXON at BOW Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams. For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom